Bristol Myers's most recent trend suggests a bullish bias. One trading opportunity on Bristol Myers is a Bull Put Spread using a strike $57.00 short put and a strike $52.00 long put offers a potential 12.87% return on risk over the next 18 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $57.00 by expiration. The full premium credit of $0.57 would be kept by the premium seller. The risk of $4.43 would be incurred if the stock dropped below the $52.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Bristol Myers is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Bristol Myers is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Bristol Myers
Bristol-Myers Signs Option Deal to Acquire Galecto Biotech
Tue, 04 Nov 2014 21:30:02 GMT
Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference
Tue, 04 Nov 2014 16:11:39 GMT
noodls – NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) will present at the Credit Suisse Annual Health Care Conference on Tuesday, November 11, 2014 in Phoenix. Charles Bancroft, executive …
Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference
Tue, 04 Nov 2014 15:00:00 GMT
Business Wire – Bristol-Myers Squibb Company will present at the Credit Suisse Annual Health Care Conference on Tuesday, November 11, 2014 in Phoenix. Charles Bancroft, executive vice president and chief financial officer, will make a formal presentation about the company at 8:30 a.m.
‘Mom Turned Into a Monster': 10,000 Seniors Go Missing in Japan
Tue, 04 Nov 2014 01:17:23 GMT
Bristol-Myers Plan to Widen Access to its Hep C Drug is Criticized
Mon, 03 Nov 2014 20:28:24 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook